Liminatus Pharma, Inc. (LIMN)

NASDAQ

$4.04

$+0.23

(+6.12%)

Pre-Market

Liminatus Pharma, Inc. (LIMN) Live Price Chart

Last updated: ⁦2026-10-02 08:35:00⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Liminatus Pharma, Inc. (LIMN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4.04, with a market capitalization of $5.01M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.29 to $141.50. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$5.01M
Open	$3.81
Day's High	$1,683.00
Day's Low	$3.29
Previous Close	$3.75
Volume	105.00
Average Volume	484.56K
P/E Ratio	--
52-Week High	$141.50
52-Week Low	$3.29
Dividend Yield	--
Earnings Date	--

Liminatus Pharma, Inc. (LIMN) Pre-Market Stock Price

Liminatus Pharma, Inc. (LIMN) is trading at $4.04 in pre-market trading as of 2026-10-02 08:14:00, up 7.71% ($0.29) from the previous close of $3.75

Pre-market trading shows how investors are pricing LIMN before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.

Liminatus Pharma, Inc. (LIMN) 7-Day Stock Price Change

Over the past seven days, Liminatus Pharma, Inc. (LIMN) moved from $4.03 to $4.04, representing a gain of 0.22% ($0.01).

The stock traded between $3.65 and $4.48 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.

The average daily volume was 21.09 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

LIMN 52-Week Price Position

Position in Range: 0.5%

52W Low$3.29

52W High$141.50

LIMN is currently trading at $4.04, placing it 0.5% of the way from its 52-week low of $3.29 to its 52-week high of $141.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Liminatus Pharma, Inc. (LIMN)?

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.

Liminatus Pharma, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	1
Exchange	NASDAQ
Company Website	http://liminatuspharma.com

How to Buy Liminatus Pharma, Inc. (LIMN) Stock on MEXC

Eligible investors can buy real shares of Liminatus Pharma, Inc. (LIMN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for LIMN and Place Your Order

Open the RealStocks trading page and search for LIMN. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Liminatus Pharma, Inc. (LIMN) stock price today?

Liminatus Pharma, Inc. (LIMN) is currently trading at $ 4.04, up 7.71% ($0.29) from the previous close of $ 3.75. Intraday prices update in real time during regular trading hours.

2.Is LIMN stock going up or down today?

As of 2026-10-02 08:14:00, LIMN is trading at $ 4.04, up 7.71% ($0.29) from its previous close of $ 3.75. The stock has traded between $ 3.29 and $ 1,683.00 during today’s regular session. Past price movements do not guarantee future results.

3.What is LIMN pre-market price?

As of 2026-10-02 08:14:00, LIMN is trading at $ 4.04 in pre-market trading, up 7.71% ($0.29) from the previous close of $ 3.75. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is LIMN after-hours price?

As of 2026-10-02 08:14:00, LIMN is trading at $ 3.79 in after-hours trading, up 0.93% ($0.04) from the regular-session close of $ 3.75. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is LIMN stock trading now?

LIMN trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does LIMN sit relative to its 52-week high and low?

Over the past 52 weeks, LIMN has traded between a low of $ 3.29 and a high of $ 141.50. At $ 4.04, the stock is positioned 0.5% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Liminatus Pharma, Inc. in?

Liminatus Pharma, Inc. (LIMN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Liminatus Pharma, Inc.'s market capitalization and where is it listed?

Liminatus Pharma, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 5.01M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is LIMN valued in terms of P/E ratio and EPS?

LIMN trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Liminatus Pharma, Inc. pay a dividend?

Liminatus Pharma, Inc. pays an indicated annual cash dividend of -- per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.